Codebreak300: Sotorasib Plus Panitumumab in KRAS G12C-Mutated Metastatic Colorectal Cancer

Commentary
Video

Rachna Shroff, MD, chief of the Division of Hematology and Oncology in the Department of Medicine at the University of Arizona College of Medicine, highlights key data from the Codebreak300 study evaluating if the combination of sotorasib and panitumumab is superior to standard-of-care trifluridine/tipiracil or regorafenib in the setting of chemorefractory metastatic colorectal cancer.

Recent Videos
3 KOLs are featured in this series.
3 KOLs are featured in this series.
3 KOLs are featured in this series.
3 KOLs are featured in this series.
Related Content
Adding Bevacizumab Improves PFS, But Not OS, in Advanced Biliary Tract Cancer

Adding Bevacizumab Improves PFS, But Not OS, in Advanced Biliary Tract Cancer

Sabrina Serani
November 6th 2024
Article

Bevacizumab in combination with atezolizumab and chemotherapy led to improvements in progression-free survival and duration of response in patients with advanced biliary tract cancer.

Read More

LaPelusa’s Journey in the Dynamic Field of GI Oncology

LaPelusa’s Journey in the Dynamic Field of GI Oncology

Jordyn Sava;Michael LaPelusa, MD
May 1st 2024
Podcast

In this episode of Emerging Experts, Michael LaPelusa, MD, shares his insights, experiences, and passion for cancer research, particularly in the realm of gastrointestinal cancers.

Listen

Lenvatinib/Pembrolizumab/TACE Regimen Improves PFS in Intermediate-Stage HCC

Lenvatinib/Pembrolizumab/TACE Regimen Improves PFS in Intermediate-Stage HCC

Jordyn Sava
October 28th 2024
Article

Josep M. Llovet, MD, PhD, discussed the updated data from the LEAP-012 trial in intermediate-stage hepatocellular carcinoma.

Read More

Behind the FDA Approval of Fruquintinib for Previously Treated mCRC

Behind the FDA Approval of Fruquintinib for Previously Treated mCRC

Jordyn Sava;Arvind Dasari, MD, MS
November 15th 2023
Podcast

In season 4, episode 18 of Targeted Talks, Arvind Dasari, MD, MS, dives into the recent approval of fruquintinib for patients with metastatic colorectal cancer.

Listen

FDA Pushes Back Decision on Sotorasib/Panitumumab in Colorectal Cancer

FDA Pushes Back Decision on Sotorasib/Panitumumab in Colorectal Cancer

Sabrina Serani
October 18th 2024
Article

The FDA was expected to decide on the application of sotorasib and panitumumab for the treatment of metastatic colorectal cancer on October 17, 2024.

Read More

Trial of PT886 and Pembrolizumab Doses First Patient With Gastric/GEJ Cancer

Trial of PT886 and Pembrolizumab Doses First Patient With Gastric/GEJ Cancer

Jordyn Sava
October 10th 2024
Article

The first patient with advanced gastric and gastroesophageal cancer has been dosed in a trial combining PT886 with pembrolizumab.

Read More